Biotie Therapies Corp. Announces That the Delisting of Its American Depositary Shares from NASDAQ Global Select Market Has Be...
13 6월 2016 - 10:30PM
Business Wire
Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) (“Biotie”
or the “Company”) announces that the voluntary delisting of
its American Depositary Shares (“ADSs”) from the NASDAQ
Global Select Market (“Nasdaq US”) became effective prior to
the opening of trading on 13 June, 2016, following the filing, on 2
June 2016, of an application on Form 25 with the U.S. Securities
and Exchange Commission (the “SEC”) for notifying the SEC of
the delisting of the Company’s ADSs from NASDAQ US, as announced on
18 May 2016.
The delisting becoming effective means that the ADSs are no
longer tradable on any regulated security exchange. Biotie shares
(“Shares”) will remain listed on Nasdaq Helsinki Ltd.,
although the Company intends to delist the Shares from Nasdaq
Helsinki Ltd. as soon as permitted and practicable under applicable
laws.
Further details on Biotie’s reporting obligations under
applicable U.S. securities laws after the delisting of the ADSs
becoming effective and the treatment of the ADSs in the compulsory
redemption proceedings initiated by Acorda Therapeutics,
Inc.("Acorda") for Biotie's minority shares under the Finnish
Companies Act have been described in the stock exchange release
issued by Biotie on 18 May 2016.
INFORMATION REGARDING BIOTIE
Biotie is a biopharmaceutical company focused on products for
neurodegenerative and psychiatric disorders. Biotie's development
has delivered Selincro (nalmefene) for alcohol dependence, which
received European marketing authorization in 2013 and is currently
being rolled out across Europe by partner H. Lundbeck A/S. The
current development products include tozadenant for Parkinson's
disease, which is in Phase 3 development, and two additional
compounds which are in Phase 2 development for cognitive disorders
including Parkinson's disease dementia, and primary sclerosing
cholangitis (PSC), a rare fibrotic disease of the liver.
For more information, please visit www.biotie.com.
INFORMATION REGARDING ACORDA
Founded in 1995, Acorda is a biotechnology company focused on
developing therapies that restore function and improve the lives of
people with neurological disorders, with its common stock listed on
Nasdaq US.
Acorda has an industry leading pipeline of novel neurological
therapies addressing a range of disorders, including Parkinson’s
disease, epilepsy, post-stroke walking deficits, migraine, and
multiple sclerosis. Acorda markets three FDA-approved therapies,
including AMPYRA® (dalfampridine) Extended Release Tablets, 10
mg.
For more information, please visit www.acorda.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS
Some of the statements contained in this announcement are
forward-looking statements, including Biotie’s deregistration from
U.S. reporting obligations, which involve a number of risks and
uncertainties. These statements are based on current expectations,
assumptions, estimates and projections, and involve known and
unknown risks, uncertainties and other factors that may cause
results, levels of activity, performance or achievements to be
materially different from any future statements. These statements
are generally identified by words or phrases such as “believe”,
“anticipate”, “expect”, “intend”, “plan”, “will”, “may”, “should”,
“estimate”, “predict”, “potential”, “continue” or the negative of
such terms or other similar expressions. If underlying assumptions
prove inaccurate or unknown risks or uncertainties materialize,
actual results and the timing of events may differ materially from
the expected results and/or timing discussed in the forward-looking
statements, and you should not place undue reliance on these
statements. Acorda and Biotie disclaim any intent or obligation to
update any forward-looking statements as a result of developments
occurring after the period covered by this announcement or
otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160613005725/en/
Biotie Therapies Corp.Virve Nurmi, +358 2 274
8900virve.nurmi@biotie.comorAcorda Therapeutics,Inc.Felicia
Vonella, 914-326-5146fvonella@acorda.com
BIOTIE THERAPIES CORP. (NASDAQ:BITI)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
BIOTIE THERAPIES CORP. (NASDAQ:BITI)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024